Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1965 1
1966 1
1974 1
1981 2
1983 2
1985 1
1986 4
1987 5
1988 2
1989 3
1990 5
1991 4
1993 2
1994 1
1995 1
1996 2
1997 2
1998 1
1999 1
2000 1
2001 2
2002 1
2003 6
2004 7
2005 9
2006 11
2007 14
2008 13
2009 14
2010 14
2011 17
2012 17
2013 35
2014 25
2015 16
2016 27
2017 23
2018 23
2019 23
2020 28
2021 36
2022 24
2023 32
2024 27
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

442 results

Results by year

Filters applied: . Clear all
Page 1
Tocilizumab and immune signatures for targeted management of cytokine release syndrome in immune checkpoint therapy.
Daoudlarian D, Segot A, Latifyan S, Bartolini R, Joo V, Mederos N, Bouchaab H, Demicheli R, Abdelhamid K, Ferahta N, Doms J, Stalder G, Noto A, Mencarelli L, Mosimann V, Berthold D, Stravodimou A, Sartori C, Shabafrouz K, Thompson JA, Wang Y, Peters S, Pantaleo G, Obeid M. Daoudlarian D, et al. Among authors: noto a. Ann Oncol. 2024 Dec 17:S0923-7534(24)04979-2. doi: 10.1016/j.annonc.2024.12.004. Online ahead of print. Ann Oncol. 2024. PMID: 39701282 Free article.
First-line treatment of Waldenström's macroglobulinemia in Italy: A multicenter real-life study on 547 patients to evaluate the long-term efficacy and tolerability of different chemoimmunotherapy strategies.
Autore F, Tedeschi A, Benevolo G, Mattiello V, Galli E, Danesin N, Rizzi R, Olivieri J, Cencini E, Puccini B, Ferrarini I, Marino D, Bullo M, Rossini B, Motta M, Innocenti I, Fresa A, Stirparo L, Petrilli D, Pasquale R, Musto P, Scapinello G, Noto A, Peri V, Zamprogna G, Hohaus S, Frustaci AM, Piazza F, Ferrero S, Laurenti L. Autore F, et al. Among authors: noto a. Am J Hematol. 2025 Jan;100(1):189-191. doi: 10.1002/ajh.27524. Epub 2024 Nov 19. Am J Hematol. 2025. PMID: 39560301 No abstract available.
Long-Term Clinical and Sustained REMIssion in Severe Eosinophilic Asthma Treated With Mepolizumab: The REMI-M Study.
Crimi C, Nolasco S, Noto A, Maglio A, Quaranta VN, Di Bona D, Scioscia G, Papia F, Caiaffa MF, Calabrese C, D'Amato M, Pelaia C, Campisi R, Vitale C, Ciampo L, Dragonieri S, Minenna E, Massaro F, Gallotti L, Macchia L, Triggiani M, Scichilone N, Valenti G, Pelaia G, Foschino Barbaro MP, Carpagnano GE, Vatrella A, Crimi N; Southern Italy Network on Severe Asthma Therapy. Crimi C, et al. Among authors: noto a. J Allergy Clin Immunol Pract. 2024 Dec;12(12):3315-3327. doi: 10.1016/j.jaip.2024.08.033. Epub 2024 Aug 27. J Allergy Clin Immunol Pract. 2024. PMID: 39197750 Free article.
442 results